Pharmaceutical drug
Brazikumab Type Whole antibody Source Human Target IL23 Other names MEDI2070 ATC code CAS Number ChemSpider UNII KEGG Formula C 6410 H 9830 N 1718 O 2016 S 50 Molar mass 144820 .16 g·mol−1
Brazikumab (INN; development code MEDI2070 ) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1] [2] that targets IL-23.[3]
This drug was developed by MedImmune.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF) . WHO Drug Information . 30 (2).
^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy . 20 (4): 399–406. doi:10.1080/14712598.2020.1697227 . PMID 31760827.
Last Update: 2023-12-20T19:21:01Z
Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease. that targets IL-23. This drug...
Word Count : 98
Last Update: 2024-04-30T22:50:27Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1841
Last Update: 2024-04-30T02:45:01Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1922
Last Update: 2024-04-07T06:14:24Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1152
Last Update: 2024-04-30T04:40:36Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 3592
Last Update: 2024-05-12T04:34:23Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1017
Last Update: 2024-03-15T07:13:16Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2070
Last Update: 2024-04-17T06:53:02Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2577
Last Update: 2024-04-20T03:30:36Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 267
Last Update: 2024-02-26T14:00:14Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1578
Last Update: 2023-12-01T20:57:17Z
Human Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab...
Word Count : 4304
Last Update: 2024-05-08T15:44:25Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 7480
Last Update: 2024-03-28T06:50:00Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 3305
Last Update: 2024-05-02T12:36:27Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 4194
Last Update: 2024-03-08T11:05:29Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2293
Last Update: 2024-04-29T05:37:30Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 4990
Last Update: 2024-04-10T06:41:00Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1145
Last Update: 2024-04-07T05:29:31Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1629
Last Update: 2024-04-11T19:32:12Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2761
Last Update: 2023-12-20T20:04:18Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 587
Last Update: 2024-02-26T19:50:00Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2392
Last Update: 2024-04-29T03:54:23Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1263
Last Update: 2024-01-27T04:17:51Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 716
Last Update: 2024-04-09T15:15:21Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 4858
Last Update: 2024-03-13T06:37:38Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1478
Last Update: 2023-12-14T00:18:50Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 1675
Last Update: 2024-04-02T19:00:39Z
Fezakinumab (against IL-22) IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists:...
Word Count : 2548